

REMARKS

Claims 1, 2, 7, 10, 11-25, 26, and 29-34 are pending. Claims 31, 32, 33, and 34 have been added and correspond to the subject matter of Group I. These new claims are fully supported by the originally-filed specification. Claim 33 is supported, for instance, by the disclosure at page 15, lines 1-5, of the specification. Claims 2, 10, and 26 have been amended. Claims 3-6, 8-9, and 27-28 have been cancelled. Claims 11-25 and 29-30 have been withdrawn. Of course, Applicants reserve the right to file one or more continuing applications to the cancelled and non-elected subject matter. The Examiner issued a 5-way restriction requirement according to the following groups, and indicated that Applicants must elect a single nucleic acid sequence from SEQ ID NOs. 1-6, regardless of the elected group.

Group I (claims 1-10 and 26-28), to MKK nucleic acids, vectors, host cells;

Group II (claims 11-13), drawn to antisense molecules;

Group III (claims 14-22), drawn to MKK proteins;

Group IV (claims 23-25), drawn to MKK antibodies; and

Group V (claims 29 and 30), drawn to a method of inhibiting signal transduction.

Accordingly, Applicants provisionally elect Group I, *i.e.*, claims 1-10, 26-28, and newly added claims 31-34, and SEQ ID NO. 2, the amino acid sequence of MKK1, with traverse.

Date July 18, 2003

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Respectfully submitted,

By 

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087